About Thymosin Alpha-1 Reviews

What this site is

Thymosin Alpha-1 Reviews is an independent editorial project that publishes summaries of the peer-reviewed research literature on Thymosin Alpha-1 (thymalfasin). We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The "reviews" in our name is an evidence-appraisal stance, not a rating service and not a vendor signal. It means we weigh the published record — saying plainly what is established, what is suggestive, and what failed. We hold the strong results (chronic hepatitis B) apart from the negative ones (the null phase-3 sepsis trial), and we report findings as study-attributed, never upgrading "studied" to "proven."

How we read the record

Our editorial lens is immune tolerance and autoimmunity — the dual character of a peptide that both stimulates and regulates the immune system. We aim for accuracy first: Thymosin Alpha-1 is an immunomodulatory thymic peptide, not an anabolic or performance compound, and we keep it strictly distinct from the peptides it is confused with — thymosin beta-4 (the actin-binding peptide sold as TB-500), thymulin, thymopentin, thymalin, and its precursor prothymosin alpha. Every quantitative claim on this site maps to a numbered source on the references page.

What the modifier means

A domain modifier like "reviews" describes the position this publisher occupies relative to the literature — an appraisal desk — not a claim about services we offer. We do not diagnose, treat, prescribe, or sell. Thymosin Alpha-1 is not approved for marketing in the United States, and nothing here should be read as encouragement to obtain or use it outside of approved medical settings. We summarize research; readers make their own decisions with qualified professionals.